000274096 001__ 274096
000274096 005__ 20250119000331.0
000274096 0247_ $$2doi$$a10.1016/j.euroneuro.2024.12.001
000274096 0247_ $$2ISSN$$a0924-977X
000274096 0247_ $$2ISSN$$a1873-7862
000274096 0247_ $$2altmetric$$aaltmetric:172417781
000274096 0247_ $$2pmid$$apmid:39718074
000274096 037__ $$aDZNE-2025-00052
000274096 082__ $$a610
000274096 1001_ $$00000-0003-4407-9454$$aMontejo, Laura$$b0
000274096 245__ $$aContrasting genetic burden for bipolar disorder: Early onset versus late onset in an older adult bipolar disorder sample
000274096 260__ $$aAmsterdam$$bElsevier$$c2025
000274096 3367_ $$2DRIVER$$aarticle
000274096 3367_ $$2DataCite$$aOutput Types/Journal article
000274096 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736941328_13620
000274096 3367_ $$2BibTeX$$aARTICLE
000274096 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274096 3367_ $$00$$2EndNote$$aJournal Article
000274096 520__ $$aOlder Adults with Bipolar Disorder (OABD) represent a heterogeneous group, including those with early and late onset of the disorder. Recent evidence shows both groups have distinct clinical, cognitive, and medical features, tied to different neurobiological profiles. This study explored the link between polygenic risk scores (PRS) for bipolar disorder (PRS-BD), schizophrenia (PRS-SCZ), and major depressive disorder (PRS-MDD) with age of onset in OABD. PRS-SCZ, PRS-BD, and PRS-MDD among early vs late onset were calculated. PRS was used to infer posterior SNP effect sizes using a fully Bayesian approach. Demographic, clinical, and cognitive variables were also analyzed. Logistic regression analysis was used to estimate the amount of variation of each group explained by standardized PRS-SCZ, PRS-MDD, and PRS-BD. A total of 207 OABD subjects were included (144 EOBD; 63 LOBD). EOBD showed higher PRS-BD compared to LOBD (p = 0.005), while no association was found between age of onset and PRS-SCZ or PRS-MDD. Compared to LOBD, EOBD individuals also showed a higher likelihood for suicide attempts (p = 0.01), higher presence of psychotic symptoms (p = 0.003), higher prevalence of BD-I (p = 0.002), higher rates of familiarity for any psychiatric disorder (p = 0.004), and lower processing speed measured with Trail-Making Test part A (p = 0.03). OABD subjects with an early onset showed a greater genetic burden for BD compared to subjects with a late onset. These findings contribute to the notion that EOBD and LOBD may represent different forms of OABD, particularly regarding the genetic predisposition to BD.
000274096 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274096 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000274096 7001_ $$00000-0003-1673-8248$$aSole, Brisa$$b1
000274096 7001_ $$aFico, Giovanna$$b2
000274096 7001_ $$aKalman, Janos L.$$b3
000274096 7001_ $$00000-0001-7301-9157$$aBudde, Monika$$b4
000274096 7001_ $$0P:(DE-2719)9000977$$aHeilbronner, Urs$$b5
000274096 7001_ $$00000-0002-5961-6032$$aOliva, Vincenzo$$b6
000274096 7001_ $$00000-0002-2032-1181$$aDe Prisco, Michele$$b7
000274096 7001_ $$00009-0008-4675-8358$$aMartin-Parra, Sara$$b8
000274096 7001_ $$aRuiz, Andrea$$b9
000274096 7001_ $$aMartinez-Aran, Anabel$$b10
000274096 7001_ $$aAdorjan, Kristina$$b11
000274096 7001_ $$aFalkai, Peter$$b12
000274096 7001_ $$aHeilbronner, Maria$$b13
000274096 7001_ $$00000-0002-1357-2636$$aKohshour, Mojtaba Oraki$$b14
000274096 7001_ $$00000-0001-7818-539X$$aReich-Erkelenz, Daniela$$b15
000274096 7001_ $$aSchaupp, Sabrina K.$$b16
000274096 7001_ $$00000-0003-3105-5672$$aSchulte, Eva C.$$b17
000274096 7001_ $$aSenner, Fanny$$b18
000274096 7001_ $$aVogl, Thomas$$b19
000274096 7001_ $$aAnghelescu, Ion-George$$b20
000274096 7001_ $$aArolt, Volker$$b21
000274096 7001_ $$aBaune, Bernhard T.$$b22
000274096 7001_ $$aDannlowski, Udo$$b23
000274096 7001_ $$aDietrich, Detlef E.$$b24
000274096 7001_ $$0P:(DE-HGF)0$$aFallgatter, Andreas J.$$b25
000274096 7001_ $$aFigge, Christian$$b26
000274096 7001_ $$aJuckel, Georg$$b27
000274096 7001_ $$aKonrad, Carsten$$b28
000274096 7001_ $$00009-0007-5406-5319$$aReimer, Jens$$b29
000274096 7001_ $$00000-0001-5964-4087$$aReininghaus, Eva Z.$$b30
000274096 7001_ $$aSchmauß, Max$$b31
000274096 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b32$$udzne
000274096 7001_ $$aZimmermann, Jörg$$b33
000274096 7001_ $$00000-0002-0548-0053$$aVieta, Eduard$$b34
000274096 7001_ $$00000-0001-9366-8728$$aPapiol, Sergi$$b35
000274096 7001_ $$aSchulze, Thomas G.$$b36
000274096 7001_ $$aTorrent, Carla$$b37
000274096 773__ $$0PERI:(DE-600)2019305-1$$a10.1016/j.euroneuro.2024.12.001$$gVol. 92, p. 29 - 37$$p29 - 37$$tEuropean neuropsychopharmacology$$v92$$x0924-977X$$y2025
000274096 8564_ $$uhttps://pub.dzne.de/record/274096/files/DZNE-2025-00052.pdf$$yOpenAccess
000274096 8564_ $$uhttps://pub.dzne.de/record/274096/files/DZNE-2025-00052.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274096 909CO $$ooai:pub.dzne.de:274096$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274096 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b32$$kDZNE
000274096 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274096 9141_ $$y2025
000274096 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR NEUROPSYCHOPHARM : 2022$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274096 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR NEUROPSYCHOPHARM : 2022$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000274096 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000274096 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000274096 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000274096 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000274096 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000274096 980__ $$ajournal
000274096 980__ $$aVDB
000274096 980__ $$aUNRESTRICTED
000274096 980__ $$aI:(DE-2719)1410006
000274096 9801_ $$aFullTexts